Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 5/20 | 0.47 |
| ▸ | COMT | P21964 | 4/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GALK1 | P51570 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32670118 | 0.89 | FTO (0.60) | FTOCOMTEGFRALDH1A1MEN1 | |
| SCHEMBL32669800 | 0.89 | COMT (0.42) | FTOCOMT | |
| SCHEMBL32669799 | 0.87 | FTO (0.43) | FTOCOMTEGFRALDH1A1MEN1 | |
| SCHEMBL32669976 | 0.87 | FTO (0.40) | FTOCOMT | |
| SCHEMBL32669876 | 0.85 | ACHE (0.41) | FTOCOMTALDH1A1MEN1POLB | |
| SCHEMBL32669743 | 0.82 | MEN1 (0.39) | FTOCOMTALDH1A1MEN1POLB | |
| SCHEMBL32669805 | 0.82 | S1PR3 (0.42) | FTOCOMTALDH1A1MEN1KMT2A | |
| SCHEMBL32670060 | 0.81 | COMT (0.43) | FTOCOMTALDH1A1POLBHPGD | |
| SCHEMBL32669797 | 0.81 | FTO (0.69) | FTOCOMTALDH1A1MEN1MAPT | |
| SCHEMBL32669494 | 0.80 | FTO (0.67) | FTOCOMTEGFRALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | FTO 1/4885COMT 52/4885EGFR 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.